Awaiting expanded approvals, Lilly and J&J release late-stage data for Crohn's treatments
Eli Lilly and Johnson & Johnson both touted data Monday for their IL-23 inhibitors in Crohn’s disease, with Lilly also sharing long-term data in ulcerative …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.